Encompass Health Corporation
EHC
$99.25
-$0.42-0.42%
| Weiss Ratings | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C+ | |||
| Reward Grade | B+ | |||
| Rating Factors | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Weak | |||
| Growth Index | Excellent | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.53 | |||
| Price History | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.03% | |||
| 30-Day Total Return | 4.18% | |||
| 60-Day Total Return | -3.00% | |||
| 90-Day Total Return | 5.04% | |||
| Year to Date Total Return | 8.06% | |||
| 1-Year Total Return | 29.22% | |||
| 2-Year Total Return | 84.86% | |||
| 3-Year Total Return | 91.77% | |||
| 5-Year Total Return | 90.52% | |||
| 52-Week High % Change | -4.67% | |||
| 52-Week Low % Change | 34.20% | |||
| Price | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $104.55 | |||
| 52-Week Low Price | $74.27 | |||
| 52-Week Low Price (Date) | Mar 15, 2024 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.04B | |||
| Enterprise Value | 13.45B | |||
| Price/Earnings (TTM) | 22.34 | |||
| Earnings Per Share (TTM) | 4.46 | |||
| Earnings Per Share Growth | 28.28% | |||
| Price/Earnings To Growth | 0.79 | |||
| Price/Sales (TTM) | 1.90 | |||
| Price/Book (Q) | 4.86 | |||
| Enterprise Value/Revenue (TTM) | 2.50 | |||
| Price | $99.25 | |||
| Enterprise Value/EBITDA (TTM) | 11.55 | |||
| Enterprise Value/EBIT | 15.56 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 102.30M | |||
| Dividend Yield | 0.64% | |||
| Div. Per Share (Most Recent) | $0.17 | |||
| Dividend Per Share (TTM) | $0.64 | |||
| Payout Ratio (TTM) | 13.78% | |||
| Dividend Per Share (Most Recent) | $0.17 | |||
| Company Info | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 205 967 7116 | |||
| Address | 9001 Liberty Parkway Birmingham, AL 35242 | |||
| Website | www.encompasshealth.com | |||
| Country | United States | |||
| Year Founded | 1984 | |||
| Profitability | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 16.08% | |||
| Profit Margin | 8.48% | |||
| Management Effectiveness | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 8.55% | |||
| Return on Equity | 23.29% | |||
| Income Statement | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.37B | |||
| Total Revenue (TTM) | 5.37B | |||
| Revenue Per Share | $52.52 | |||
| Gross Profit (TTM) | 2.23B | |||
| EBITDA (TTM) | 1.16B | |||
| EBIT (TTM) | 864.50M | |||
| Net Income (TTM) | 455.70M | |||
| Net Income Avl. to Common (TTM) | 455.70M | |||
| Total Revenue Growth (Q YOY) | 12.69% | |||
| Earnings Growth (Q YOY) | 28.37% | |||
| EPS Diluted (TTM) | 4.46 | |||
| EPS Diluted Growth (Q YOY) | 36.93% | |||
| Balance Sheet | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 85.40M | |||
| Cash Per Share (Q) | $0.83 | |||
| Total Current Assets (Q) | 886.90M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.85B | |||
| Current Ratio (Q) | 1.055 | |||
| Book Value Per Share (Q) | $20.51 | |||
| Total Assets (Q) | 6.53B | |||
| Total Current Liabilities (Q) | 841.00M | |||
| Total Debt (Q) | 2.71B | |||
| Total Liabilities (Q) | 3.69B | |||
| Total Common Equity (Q) | 2.07B | |||
| Cash Flow | EHC - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -653.30M | |||
| Cash from Financing (TTM) | -330.60M | |||
| Net Change in Cash (TTM) | 18.90M | |||
| Levered Free Cash Flow (TTM) | 209.34M | |||
| Cash from Operations (TTM) | 1.00B | |||
